SABSW
SAB Biotherapeutics, Inc.
Price Chart
Latest Quote
$0.01
-0.00 (-2.91%)
Current Price
| Previous Close | $0.01 |
| Open | $0.05 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 55,635 |
Stock Information
| Total Debt | $6.17M |
| Cash Equivalents | $107.39M |
| Net Income | $-9.41M |
| P/E Ratio | 0.03 |
| EPS (TTM) | $0.29 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-9.41M |
| Book/sh | $3.00 |
| Employees | 86 |
Financial Ratios
| Quick Ratio | 11.06 |
| Current Ratio | 11.45 |
| Debt/Eq | 2.72 |
Returns & Margins
| ROA | -25.37% |
| ROE | -0.32% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | nan |
| ATR | nan |
| Shares Float | 52.34M |
| Rel Volume | 20.00 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| YTD | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $nan | 55,635 |
| 2026-06-12 | $0.04 | 0 |
| 2026-06-11 | $0.04 | 0 |
| 2026-06-10 | $0.04 | 0 |
| 2026-06-09 | $0.04 | 0 |
| 2026-06-08 | $0.04 | 0 |
| 2026-06-05 | $0.04 | 0 |
| 2026-06-04 | $0.04 | 0 |
| 2026-06-03 | $0.04 | 0 |
| 2026-06-02 | $0.04 | 0 |
| 2026-06-01 | $0.04 | 0 |
| 2026-05-29 | $0.04 | 0 |
| 2026-05-28 | $0.04 | 0 |
| 2026-05-27 | $0.04 | 0 |
| 2026-05-26 | $0.04 | 0 |
| 2026-05-22 | $0.04 | 0 |
| 2026-05-21 | $0.04 | 0 |
| 2026-05-20 | $0.04 | 0 |
| 2026-05-19 | $0.04 | 0 |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
đ° Latest News
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
Insider Monkey âĸ 2026-05-20T20:43:44Z
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
Simply Wall St. âĸ 2026-05-15T11:32:16Z
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
GuruFocus.com âĸ 2026-05-12T23:03:26ZSAB Biotherapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-12T17:14:24Z
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks âĸ 2025-08-07T14:00:05Z
SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell
MT Newswires âĸ 2025-07-21T12:07:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $240,664 | $318,401 | $315,284 | $301,584 |
| Total Expenses | $48,953,363 | $42,910,520 | $38,075,320 | $28,917,617 |
| Other Income Expense | $61,035,678 | $7,837,614 | $-4,388,148 | $10,432,954 |
| Other Non Operating Income Expenses | $-1,718,508 | $2,452,605 | $435,089 | $33,754 |
| Net Non Operating Interest Income Expense | $1,191,368 | $967,597 | $269,682 | $-230,512 |
| Interest Expense Non Operating | $240,664 | $318,401 | $315,284 | $301,584 |
| Operating Expense | $48,953,363 | $42,910,520 | $38,075,320 | $28,917,617 |
| General And Administrative Expense | $14,601,031 | $13,981,263 | $23,799,306 | $16,383,285 |
| Other Operating Expenses | - | $-1,322,410 | $-2,238,991 | $-23,904,181 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Net Interest Income | $1,191,368 | $967,597 | $269,682 | $-230,512 |
| Interest Income | $1,432,032 | $1,285,998 | $584,966 | $71,072 |
| Normalized Income | $-49,480,503 | $-39,490,318 | $-37,370,549 | $-26,956,172 |
| Net Income From Continuing And Discontinued Operation | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Total Operating Income As Reported | $-48,953,363 | $-42,910,520 | $-38,075,320 | $-28,917,617 |
| Average Dilution Earnings | $-62,000,073 | $0 | - | - |
| Net Income Common Stockholders | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Net Income | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Net Income Including Noncontrolling Interests | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Net Income Continuous Operations | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Pretax Income | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,715,175 |
| Interest Income Non Operating | $1,432,032 | $1,285,998 | $584,966 | $71,072 |
| Operating Income | $-48,953,363 | $-42,910,520 | $-38,075,320 | $-28,917,617 |
| Special Income Charges | - | - | - | $0 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $2,183,832 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,158,253 | $-34,379,322 | $-33,309,983 | $-25,520,913 |
| Total Unusual Items | $62,754,186 | $5,385,009 | $-4,823,237 | $10,399,200 |
| Total Unusual Items Excluding Goodwill | $62,754,186 | $5,385,009 | $-4,823,237 | $10,399,200 |
| Reconciled Depreciation | $3,081,586 | $4,792,595 | $3,745,282 | $3,291,878 |
| EBITDA (Bullshit earnings) | $16,595,933 | $-28,994,313 | $-38,133,220 | $-15,121,713 |
| EBIT | $13,514,347 | $-33,786,908 | $-41,878,502 | $-18,413,591 |
| Diluted NI Availto Com Stockholders | $-48,726,390 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Gain On Sale Of Security | $62,754,186 | $5,385,009 | $-4,823,237 | $10,399,200 |
| Research And Development | $34,352,332 | $30,251,667 | $16,515,005 | $36,438,513 |
| Selling General And Administration | $14,601,031 | $13,981,263 | $23,799,306 | $16,383,285 |
| Other Gand A | $14,601,031 | $13,981,263 | $23,799,306 | $16,383,285 |
| Tax Provision | - | - | $0 | $25,629 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $151,494,375 | $25,969,576 | $57,299,441 | $31,058,142 |
| Total Assets | $172,809,969 | $44,195,469 | $83,941,253 | $50,904,927 |
| Total Non Current Assets | $71,757,345 | $20,403,240 | $25,034,390 | $28,807,474 |
| Non Current Prepaid Assets | $5,309,345 | $220,997 | $350,230 | $467,694 |
| Non Current Deferred Assets | $150,145 | $261,105 | $0 | - |
| Investmentin Financial Assets | $46,892,882 | $0 | - | - |
| Current Assets | $101,052,624 | $23,792,229 | $58,906,863 | $22,097,453 |
| Other Current Assets | $3,513,384 | $2,976,562 | $2,340,797 | $1,493,982 |
| Receivables | $946,781 | $54,955 | $0 | $5,556,577 |
| Accrued Interest Receivable | $946,781 | $54,955 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $96,592,459 | $20,760,712 | $56,566,066 | $15,046,894 |
| Cash And Cash Equivalents | $10,502,680 | $8,897,966 | $56,566,066 | $15,046,894 |
| Accounts Receivable | - | - | $0 | $5,556,577 |
| Restricted Cash | - | - | - | $0 |
| Prepaid Assets | - | - | - | $1,493,982 |
| Debt | ||||
| Total Debt | $5,950,681 | $4,668,909 | $5,907,059 | $5,928,758 |
| Long Term Debt And Capital Lease Obligation | $4,999,312 | $3,857,067 | $4,054,260 | $4,532,511 |
| Current Debt And Capital Lease Obligation | $951,369 | $811,842 | $1,852,799 | $1,396,247 |
| Current Debt | - | $275,849 | $1,050,849 | $772,665 |
| Long Term Debt | - | - | - | $541,644 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,315,594 | $18,225,893 | $26,641,812 | $19,846,785 |
| Total Non Current Liabilities Net Minority Interest | $10,634,424 | $10,246,293 | $15,828,495 | $4,853,441 |
| Derivative Product Liabilities | $5,635,112 | $6,389,226 | $11,774,235 | $320,930 |
| Current Liabilities | $10,681,170 | $7,979,600 | $10,813,317 | $14,993,344 |
| Current Notes Payable | $0 | $275,849 | $1,050,849 | $772,665 |
| Payables And Accrued Expenses | $9,729,801 | $7,167,758 | $7,638,108 | $12,134,924 |
| Interest Payable | $21,075 | $22,443 | $77,995 | $8,192 |
| Payables | $3,145,805 | $2,173,972 | $2,407,076 | $8,639,616 |
| Accounts Payable | $3,145,805 | $1,694,722 | $945,927 | $3,679,116 |
| Current Deferred Liabilities | - | $0 | $1,322,410 | $0 |
| Other Payable | - | $479,250 | $1,461,149 | $4,910,500 |
| Total Tax Payable | - | - | $40,000 | $50,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $151,494,308 | $25,969,571 | $57,299,436 | $31,058,142 |
| Preferred Stock Equity | $67 | $5 | $5 | - |
| Total Equity Gross Minority Interest | $151,494,375 | $25,969,576 | $57,299,441 | $31,058,142 |
| Stockholders Equity | $151,494,375 | $25,969,576 | $57,299,441 | $31,058,142 |
| Gains Losses Not Affecting Retained Earnings | $186,510 | $-135,410 | $26,420 | $0 |
| Other Equity Adjustments | $186,510 | $-135,410 | $26,420 | - |
| Retained Earnings | $-110,895,167 | $-124,168,850 | $-90,063,541 | $-47,869,755 |
| Other | ||||
| Treasury Shares Number | $54,665 | $54,665 | $54,665 | $54,665 |
| Ordinary Shares Number | $47,609,899 | $9,288,868 | $9,225,494 | $5,039,426 |
| Share Issued | $47,664,564 | $9,343,533 | $9,280,159 | $5,094,091 |
| Tangible Book Value | $151,494,308 | $25,969,571 | $57,299,436 | $31,058,142 |
| Invested Capital | $151,494,308 | $26,245,420 | $58,350,285 | $32,372,451 |
| Working Capital | $90,371,454 | $15,812,629 | $48,093,546 | $7,104,109 |
| Capital Lease Obligations | $5,950,681 | $4,393,060 | $4,856,210 | $4,614,449 |
| Total Capitalization | $151,494,375 | $25,969,576 | $57,299,441 | $31,599,786 |
| Treasury Stock | $5,521,246 | $5,521,246 | $5,521,246 | $5,521,246 |
| Additional Paid In Capital | $267,719,445 | $155,794,142 | $152,856,874 | $84,448,633 |
| Capital Stock | $4,833 | $940 | $934 | $510 |
| Common Stock | $4,766 | $935 | $929 | $510 |
| Preferred Stock | $67 | $5 | $5 | $0 |
| Long Term Capital Lease Obligation | $4,999,312 | $3,857,067 | $4,054,260 | $3,990,867 |
| Current Capital Lease Obligation | $951,369 | $535,993 | $801,950 | $623,582 |
| Current Accrued Expenses | $6,583,996 | $4,993,786 | $5,231,032 | $3,495,308 |
| Investments And Advances | $46,892,882 | $0 | - | - |
| Available For Sale Securities | $46,892,882 | - | - | - |
| Net PPE | $19,404,973 | $19,921,138 | $24,684,160 | $28,339,780 |
| Accumulated Depreciation | $-17,516,462 | $-14,573,924 | $-9,911,859 | $-6,278,522 |
| Gross PPE | $36,921,435 | $34,495,062 | $34,596,019 | $34,618,302 |
| Leases | $7,064,721 | $7,064,721 | $9,296,344 | $9,296,343 |
| Construction In Progress | $759,279 | $0 | $0 | $308,317 |
| Other Properties | $17,438,911 | $15,897,136 | $14,362,851 | $14,089,041 |
| Machinery Furniture Equipment | $11,658,524 | $11,533,205 | $10,936,824 | $10,924,601 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $86,089,779 | $11,862,746 | $0 | - |
| Current Deferred Revenue | - | $0 | $1,322,410 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $2,987,365 | $1,462,173 |
| Dueto Related Parties Current | - | - | - | $0 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-45,708,267 | $-34,629,271 | $-25,316,559 | $-25,625,925 |
| Operating Activities | ||||
| Operating Cash Flow | $-44,775,111 | $-34,292,009 | $-25,119,405 | $-23,459,511 |
| Cash Flow From Continuing Operating Activities | $-44,775,111 | $-34,292,009 | $-25,119,405 | $-23,459,511 |
| Operating Gains Losses | $-62,828,153 | $-5,385,009 | $4,867,730 | $-10,415,005 |
| Investing Activities | ||||
| Capital Expenditure | $-933,156 | $-337,262 | $-197,154 | $-2,166,414 |
| Investing Cash Flow | $-121,706,130 | $-11,962,267 | $-152,704 | $-2,090,024 |
| Cash Flow From Continuing Investing Activities | $-121,706,130 | $-11,962,267 | $-152,704 | $-2,090,024 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $168,729,827 | $0 | $7,500,000 | $7,680,799 |
| Financing Cash Flow | $168,299,452 | $-1,172,626 | $66,773,137 | $1,051,411 |
| Cash Flow From Continuing Financing Activities | $168,299,452 | $-1,172,626 | $66,773,137 | $1,051,411 |
| Net Other Financing Charges | $-11,963 | $-286,036 | - | $34,340,225 |
| Net Common Stock Issuance | $168,729,827 | $0 | $0 | $2,159,553 |
| Common Stock Issuance | $168,729,827 | $0 | $0 | $7,680,799 |
| Net Preferred Stock Issuance | - | $0 | $7,500,000 | $0 |
| Preferred Stock Issuance | - | $0 | $7,500,000 | $0 |
| Repurchase Of Capital Stock | - | - | $0 | $-5,521,246 |
| Other | ||||
| Repayment Of Debt | $-418,412 | $-1,422,985 | $-1,155,639 | $-2,421,238 |
| Issuance Of Debt | $0 | $515,986 | $765,194 | $1,236,125 |
| Interest Paid Supplemental Data | $242,032 | $373,954 | $245,481 | $293,392 |
| End Cash Position | $10,502,680 | $8,897,966 | $56,566,066 | $15,046,894 |
| Beginning Cash Position | $8,897,966 | $56,566,066 | $15,046,894 | $39,545,018 |
| Effect Of Exchange Rate Changes | $-213,497 | $-241,198 | $18,144 | $0 |
| Changes In Cash | $1,818,211 | $-47,426,902 | $41,501,028 | $-24,498,124 |
| Proceeds From Stock Option Exercised | $0 | $20,409 | $59,663,582 | $76,971 |
| Net Issuance Payments Of Debt | $-418,412 | $-906,999 | $-390,445 | $-1,185,113 |
| Net Short Term Debt Issuance | $-275,849 | $-1,290,982 | - | - |
| Short Term Debt Payments | $-275,849 | $-1,290,982 | - | - |
| Net Long Term Debt Issuance | $-142,563 | $383,983 | $-390,445 | $-1,185,113 |
| Long Term Debt Payments | $-142,563 | $-132,003 | $-1,155,639 | $-2,421,238 |
| Long Term Debt Issuance | $0 | $515,986 | $765,194 | $1,236,125 |
| Net Investment Purchase And Sale | $-120,773,474 | $-11,625,005 | $0 | - |
| Sale Of Investment | $21,262,086 | $25,821,196 | $0 | - |
| Purchase Of Investment | $-142,035,560 | $-37,446,201 | $0 | - |
| Net PPE Purchase And Sale | $-932,656 | $-337,262 | $-152,704 | $-2,090,024 |
| Sale Of PPE | $500 | $0 | $44,450 | $76,390 |
| Purchase Of PPE | $-933,156 | $-337,262 | $-197,154 | $-2,166,414 |
| Change In Working Capital | $-3,685,348 | $-2,298,989 | $2,326,219 | $-237,575 |
| Change In Other Working Capital | $67,420 | $-1,345,868 | $1,709,709 | $-100,000 |
| Change In Payables And Accrued Expense | $2,424,317 | $-307,705 | $-4,416,457 | $-3,319,699 |
| Change In Accrued Expense | $941,524 | $-1,231,028 | $-1,714,737 | $-2,537,907 |
| Change In Payable | $1,482,793 | $923,323 | $-2,701,720 | $-781,792 |
| Change In Account Payable | $1,482,793 | $923,323 | $-2,701,720 | $-779,425 |
| Change In Prepaid Assets | $-5,285,259 | $-590,461 | $-523,610 | $674,552 |
| Change In Receivables | $-891,826 | $-54,955 | $5,556,577 | $2,454,131 |
| Other Non Cash Items | $172,474 | $-237,093 | $3,711,430 | $-32,208 |
| Stock Based Compensation | $5,210,647 | $2,941,796 | $2,423,720 | $2,674,203 |
| Depreciation Amortization Depletion | $3,081,586 | $4,792,595 | $3,745,282 | $3,291,878 |
| Depreciation And Amortization | $3,081,586 | $4,792,595 | $3,745,282 | $3,291,878 |
| Depreciation | $3,081,586 | $4,792,595 | $3,745,282 | $3,291,878 |
| Gain Loss On Investment Securities | $-62,828,153 | $-5,385,009 | $4,823,237 | $-10,399,200 |
| Net Income From Continuing Operations | $13,273,683 | $-34,105,309 | $-42,193,786 | $-18,740,804 |
| Changes In Account Receivables | - | $0 | $5,556,577 | $2,454,131 |
| Gain Loss On Sale Of PPE | - | $0 | $44,493 | $-15,805 |
| Common Stock Payments | - | - | $0 | $-5,521,246 |
| Change In Other Current Assets | - | - | $387,299 | $53,441 |
Fetched: 2026-06-20